Explore

Rapid Read Rapid Read
Study Warns Vitamin B3 Supplements May Aid Cancer Cell Survival, Impacting Chemotherapy

Study Warns Vitamin B3 Supplements May Aid Cancer Cell Survival, Impacting Chemotherapy

A recent study from Case Western Reserve University’s School of Medicine, published in Cancer Letters, has raised concerns about the use of vitamin B3 supplements, specifically nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and nicotinamide (NAM), in cancer treatment. These supplements are popular for boosting energy and supporting healthy aging by increasing levels of NAD+, a molecule crucial for metabolism and cellular repair. However, the study suggests that these supplements may inadvertently aid pancreatic cancer cells in surviving chemotherapy. Pancreatic cancer, known for its low five-year survival rate of 13%, poses significant treatment challenges, and any factor that affects treatment efficacy is critical. The research indicates that NAD+ supplements can enhance cancer cell energy, reduce oxidative stress, and limit DNA damage, thereby making tumors more resistant to chemotherapy.
Rapid Read Rapid Read
NCCN Foundation Awards Young Investigators to Advance Cancer Research

NCCN Foundation Awards Young Investigators to Advance Cancer Research

The National Comprehensive Cancer Network (NCCN) Foundation has announced the recipients of its 2026 Young Investigator Awards. These awards are designed to support early-career researchers in oncology, providing them with funding to explore innovative solutions to pressing cancer-related issues. The recipients, selected through a rigorous peer review process by the NCCN Oncology Research Program, include researchers from prestigious institutions such as Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, and The University of Texas MD Anderson Cancer Center. The awarded projects address various critical areas in cancer research, including melanoma treatment, pancreatic cancer resistance, and interventions for breast cancer patients with high-risk social determinants of health. The awards are supported by funding from several pharmaceutical companies and foundations, emphasizing the collaborative effort to foster future leaders in cancer research.
Rapid Read Rapid Read
Scientists Discover Mitochondrial Dysfunction in Dendritic Cells Affecting Cancer Immunotherapy

Scientists Discover Mitochondrial Dysfunction in Dendritic Cells Affecting Cancer Immunotherapy

Researchers have identified a critical reason why dendritic cells, a type of immune cell, lose their effectiveness inside tumors. The study, conducted in mice, found that the mitochondria within these cells become debilitated, impairing their ability to enlist the body's immune defenses against cancer. When dendritic cells with robust mitochondria were injected into mice with cancer, the growth of tumors slowed significantly. This discovery could have significant implications for cancer therapies that utilize the immune system, known as immunotherapies. These therapies have shown success against difficult-to-treat tumors, but their benefits are often limited or temporary. The study suggests that improving the fitness of dendritic cells could enhance the effectiveness of these treatments.
Rapid Read Rapid Read
Innovative Therapy Shows Promise in Halting Prostate Cancer Spread to Bone

Innovative Therapy Shows Promise in Halting Prostate Cancer Spread to Bone

Researchers at the VCU Massey Comprehensive Cancer Center have developed a new targeted therapy that effectively prevents prostate cancer from spreading to the bones. The therapy, involving a small molecule inhibitor called IVMT-Rx-4, has shown promising results in preclinical models by blocking the function of a gene known as MDA-9/syntenin, which is responsible for tumor growth and metastasis. This innovative approach not only halts the progression of prostate cancer to an advanced stage but also enhances the efficacy of existing chemotherapy treatments. The findings, published in Pharmacological Research, suggest a potential paradigm shift in treating metastatic prostate cancer.
Trendline Trendline
Delcath Systems to Showcase Liver Cancer Treatment at Radiology Meeting

Delcath Systems to Showcase Liver Cancer Treatment at Radiology Meeting

Delcath Systems to Showcase Liver Cancer Treatment at Radiology Meeting
Rapid Read Rapid Read
Delcath Systems to Showcase Hepatic Delivery System at Society of Interventional Radiology 2026 Meeting

Delcath Systems to Showcase Hepatic Delivery System at Society of Interventional Radiology 2026 Meeting

Delcath Systems, Inc., an interventional oncology company, is set to participate in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting in Toronto, Canada, from April 11-15, 2026. The company will feature its Hepatic Delivery System (HDS) for percutaneous hepatic perfusion in three presentations. Dr. Eric Wehrenberg-Klee from Massachusetts General Hospital will discuss his user experience with HEPZATO at the SIR Innovation Hub. Dr. David Eschelman from Thomas Jefferson University and Dr. Mustafa Ege Seker from the University of Wisconsin will present their clinical experiences with the system for treating liver metastases from uveal melanoma. Delcath's HEPZATO KIT, approved by the FDA, is designed to deliver high-dose chemotherapy to the liver while minimizing systemic exposure.
Rapid Read Rapid Read
Novel Cancer Treatment Shows Promise in Mice, Combining HIF Inhibitors with Immunotherapy

Novel Cancer Treatment Shows Promise in Mice, Combining HIF Inhibitors with Immunotherapy

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed new small molecule drugs that inhibit hypoxia-inducible factors 1 and 2 (HIF-1/2), which are key regulators of cancer progression. These drugs, when combined with immunotherapy, have shown the ability to completely eliminate various types of tumors in mice, including breast, colorectal, melanoma, and prostate cancers. The study suggests that these drugs could potentially be used to treat a wide range of cancers in humans by overcoming resistance to immune checkpoint blockade therapy.
Rapid Read Rapid Read
Epigenetic Strategy Shows Promise in Treating Acute Myeloid Leukemia

Epigenetic Strategy Shows Promise in Treating Acute Myeloid Leukemia

Researchers from The Jackson Laboratory have developed an epigenetic strategy to reactivate a tumor suppressor gene, ZBTB7A, in acute myeloid leukemia (AML) models. This approach involves inhibiting KDM4 enzymes, which are responsible for silencing the gene in AML cells. By restoring ZBTB7A expression, the researchers were able to reduce the aggressiveness of cancer cells in mice, potentially offering a less toxic alternative to chemotherapy. The study, published in Science Translational Medicine, highlights the potential for repurposing existing drug candidates to inhibit KDM4 and treat AML without harming normal blood cells.
Rapid Read Rapid Read
Feinstein Institutes Awards 2026 Ross Prize to Drs. Michel Sadelain and Carl H. June for CAR T-cell Therapy Innovations

Feinstein Institutes Awards 2026 Ross Prize to Drs. Michel Sadelain and Carl H. June for CAR T-cell Therapy Innovations

The Feinstein Institutes for Medical Research has announced that Dr. Carl H. June from the University of Pennsylvania and Dr. Michel Sadelain from Columbia University will receive the 13th annual Ross Prize in Molecular Medicine. The award ceremony is scheduled for June 11 in New York City, in collaboration with The New York Academy of Sciences. The award recognizes their pioneering work in developing CAR T-cell therapy, a groundbreaking treatment for cancer. This therapy involves genetically engineering a patient's T cells to target and destroy cancer cells, offering new hope for patients with refractory leukemias and other cancers. The Ross Prize, established in 2013, includes a $50,000 award and is presented to researchers whose work has the potential to transform disease treatment.
Trendline Trendline
AvenCell Therapeutics Begins Phase I Trial of Dual-Targeting CAR-T Therapy for B-Cell Malignancies

AvenCell Therapeutics Begins Phase I Trial of Dual-Targeting CAR-T Therapy for B-Cell Malignancies

AvenCell Therapeutics Begins Phase I Trial of Dual-Targeting CAR-T Therapy for B-Cell Malignancies
Trendline Trendline
European Commission Approves KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer

European Commission Approves KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer

European Commission Approves KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer
Rapid Read Rapid Read
University of East Anglia Identifies Unique Microbial Signature in Colorectal Cancer, Potentially Transforming Diagnosis and Treatment

University of East Anglia Identifies Unique Microbial Signature in Colorectal Cancer, Potentially Transforming Diagnosis and Treatment

Researchers at the University of East Anglia have discovered a distinct microbial 'fingerprint' in colorectal cancer, setting it apart from other cancer types. This finding, published in Science Translational Medicine, challenges the assumption that each cancer type has a unique microbial signature. The study analyzed whole genome sequencing data from over 9,000 cancer patients, revealing that only colorectal tumors consistently showed a unique microbial community. This discovery could enhance diagnostic precision and treatment strategies for colorectal cancer. The research also highlights the potential of whole genome sequencing in identifying pathogenic organisms and improving cancer care.